Related Experiment Video
Updated: Feb 4, 2026

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model
Published on: June 3, 2020
The hypoxic tight-skin mouse model of Group 3 pulmonary hypertension
L Chi1,2, A E Foley1,2, G Goodarzi2
1Department of Physiology, University of Toronto, Toronto, ON, Canada.
Abstract:
Pulmonary hypertension (PH) arising from chronic lung disease and hypoxia is a deadly condition without cure. Small animal models using hypoxia are mild, and do not fully recapitulate human disease. The tight skin mouse (Tsk+/-) possesses key characteristics of chronic lung disease, including emphysema. We sought to assess the lung vasculature in Tsk+/- mice exposed to chronic hypoxia. Tsk+/- mice and littermates were housed in normoxia or hypoxia for 4 weeks. Endpoint analysis included invasive measurement of right ventricular systolic pressure, histology, immunoblotting, and ELISA. Proliferation was measured in primary human pulmonary artery adventitial fibroblasts (PAAF) and pulmonary artery smooth muscle cells (PASMC). Tsk+/- mice demonstrated significant emphysema. Following hypoxia, Tsk+/- mice had severe PH as compared to wildtype. Tsk+/- mice had elevated circulating high mobility group box-1 (HMGB1), which was further increased in hypoxia. Treatment with the HMGB1 antagonist, P5779, protected Tsk+/- mice from PH. Tsk+/- lungs displayed increased TGF-β signaling. In vitro, TGF-β stimulated HMGB1 expression in PAAF. HMGB1 in turn stimulated PAAF and PASMC proliferation. Tsk+/- mice represent a robust model of Group 3 PH, driven by hypoxia, sensitized by elevated TGF-β signaling resulting in increased circulating HMGB1, stimulating PAAF and PASMC proliferation. The Tsk+/- model represents a novel system for studying Group 3 PH.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Tight Junctions
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

